Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment
Key takeaways
- On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy/o HCM.
- MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with oHCM.
- Cytokinetics (NASDAQ:CYTK) stated that the German launch marks the first step in a broader European rollout strategy aimed at expanding access to the therapy across the region.
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment Maham Fatima Sun, June 14, 2026 at 2:34 AM GMT+7 1 min read CYTK Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy/o HCM. The launch follows European Commission approval in February and builds on prior regulatory approvals in the US and China.
MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with oHCM. Its approval was supported by Phase 3 SEQUOIA-HCM clinical trial results, which showed statistically significant improvements across exercise capacity, symptoms, hemodynamics, and quality-of-life measures compared to placebo.
Cytokinetics (NASDAQ:CYTK) stated that the German launch marks the first step in a broader European rollout strategy aimed at expanding access to the therapy across the region. The company emphasized strong clinical outcomes and regulatory validation as key drivers supporting its global commercialization of aficamten in treating hypertrophic cardiomyopathy.